Comera Life Sciences Inc

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a

The US stock market has been brutal for biopharmaceutical companies during the past year, with plummeting valuations driving companies to reprioritize their research and development plans, lay off emp

With the Nasdaq Biotechnology Index (NBI) and the closely watched XBI biotech fund down 13.2% and 18.9%, respectively, so far this year and 20.3% and 43.6% below where they were trading a year ago, ma